Thực trạng sử dụng amikacin trên bệnh nhân nhi tại Bệnh viện Đa khoa Xanh Pôn

Abstract

Objective: To describe amikacin utilization among pediatric inpatients at Saint Paul Hospital. Subjects and method: A retrospective cross-sectional study was conducted using medical records of patients aged 3 months to < 16 years who received systemic amikacin for at least one day from 01/3/2025 to 31/5/2025. Result: A total of 230 patients were included; the median age was 1.4 years and respiratory infections accounted for 85.7%. Microbiological testing was ordered in 88.3% of patients and 45.3% of cultures were positive; nasopharyngeal specimens represented 85.7% of all samples. Amikacin was prescribed empirically in 99.6% of cases; all patients received once-daily-dose regimen in combination with other antibiotics. The median initial dose was 15.0 mg/kg/day; 80.4% were treated for 5-7 days and 3.0% underwent dose adjustment. Defervescence occurred in 91.9% of febrile patients and 97.0% has recovered or improved results by discharge. Only 20.4% had a baseline and at least one measurements suitable for acute kidney injury assessment, with one case identified acute kidney injury among 47 evaluable patients. Conclusion: Amikacin was mainly used empirically with a relatively uniform dosing regimen. Microbiological data supporting targeted therapy and renal function monitoring were limited, indicating a need to strengthen efficacy and safety monitoring during treatment.